A report that found Becton Dickinson & Co. violated government rules during clinical trials will remain sealed even though it was prominently displayed in a whistleblower trial against the company, thanks to an appeals court’s ruling.
Disclosure would undermine the public interest in self-critical analysis by companies, the Appellate Division said Wednesday in Rosenberg v. Becton Dickinson & Co., A-4158-08.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
